Cargando…

Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States

BACKGROUND: The cell-propagated inactivated quadrivalent influenza vaccine (ccIIV4) may offer improved protection in seasons where egg-derived influenza viruses undergo mutations that affect antigenicity. This study estimated the relative vaccine effectiveness (rVE) of ccIIV4 versus egg-derived inac...

Descripción completa

Detalles Bibliográficos
Autores principales: Boikos, Constantina, Fischer, Lauren, O’Brien, Dan, Vasey, Joe, Sylvester, Gregg C, Mansi, James A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326580/
https://www.ncbi.nlm.nih.gov/pubmed/33400775
http://dx.doi.org/10.1093/cid/ciaa1944
_version_ 1783731857114791936
author Boikos, Constantina
Fischer, Lauren
O’Brien, Dan
Vasey, Joe
Sylvester, Gregg C
Mansi, James A
author_facet Boikos, Constantina
Fischer, Lauren
O’Brien, Dan
Vasey, Joe
Sylvester, Gregg C
Mansi, James A
author_sort Boikos, Constantina
collection PubMed
description BACKGROUND: The cell-propagated inactivated quadrivalent influenza vaccine (ccIIV4) may offer improved protection in seasons where egg-derived influenza viruses undergo mutations that affect antigenicity. This study estimated the relative vaccine effectiveness (rVE) of ccIIV4 versus egg-derived inactivated quadrivalent influenza vaccine (eIIV4) in preventing influenza-related medical encounters in the 2018–2019 US season. METHODS: A dataset linking primary care electronic medical records with medical claims data was used to conduct a retrospective cohort study among individuals ≥ 4 years old vaccinated with ccIIV4 or eIIV4 during the 2018–2019 season. Adjusted odds ratios (ORs) were derived from a doubly robust inverse probability of treatment-weighted approach adjusting for age, sex, race, ethnicity, geographic region, vaccination week, and health status. rVE was estimated by (1 – OR) × 100 and presented with 95% confidence intervals (CI). RESULTS: Following the application of inclusion/exclusion criteria, the study cohort included 2 125 430 ccIIV4 and 8 000 903 eIIV4 recipients. Adjusted analyses demonstrated a greater reduction in influenza-related medical encounters with ccIIV4 versus eIIV4, with the following rVE: overall, 7.6% (95% CI, 6.5–8.6); age 4–17 years, 3.9% (95% CI, .9–7.0); 18–64 years, 6.5% (95% CI, 5.2–7.9); 18–49 years, 7.5% (95% CI, 5.7–9.3); 50–64 years, 5.6% (95% CI, 3.6–7.6); and ≥65 years, –2.2% (95% CI, –5.4 to .9). CONCLUSIONS: Adjusted analyses demonstrated statistically significantly greater reduction in influenza-related medical encounters in individuals vaccinated with ccIIV4 versus eIIV4 in the 2018–2019 US influenza season. These results support ccIIV4 as a potentially more effective public health measure against influenza than an egg-based equivalent.
format Online
Article
Text
id pubmed-8326580
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-83265802021-08-02 Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States Boikos, Constantina Fischer, Lauren O’Brien, Dan Vasey, Joe Sylvester, Gregg C Mansi, James A Clin Infect Dis Online Only Articles BACKGROUND: The cell-propagated inactivated quadrivalent influenza vaccine (ccIIV4) may offer improved protection in seasons where egg-derived influenza viruses undergo mutations that affect antigenicity. This study estimated the relative vaccine effectiveness (rVE) of ccIIV4 versus egg-derived inactivated quadrivalent influenza vaccine (eIIV4) in preventing influenza-related medical encounters in the 2018–2019 US season. METHODS: A dataset linking primary care electronic medical records with medical claims data was used to conduct a retrospective cohort study among individuals ≥ 4 years old vaccinated with ccIIV4 or eIIV4 during the 2018–2019 season. Adjusted odds ratios (ORs) were derived from a doubly robust inverse probability of treatment-weighted approach adjusting for age, sex, race, ethnicity, geographic region, vaccination week, and health status. rVE was estimated by (1 – OR) × 100 and presented with 95% confidence intervals (CI). RESULTS: Following the application of inclusion/exclusion criteria, the study cohort included 2 125 430 ccIIV4 and 8 000 903 eIIV4 recipients. Adjusted analyses demonstrated a greater reduction in influenza-related medical encounters with ccIIV4 versus eIIV4, with the following rVE: overall, 7.6% (95% CI, 6.5–8.6); age 4–17 years, 3.9% (95% CI, .9–7.0); 18–64 years, 6.5% (95% CI, 5.2–7.9); 18–49 years, 7.5% (95% CI, 5.7–9.3); 50–64 years, 5.6% (95% CI, 3.6–7.6); and ≥65 years, –2.2% (95% CI, –5.4 to .9). CONCLUSIONS: Adjusted analyses demonstrated statistically significantly greater reduction in influenza-related medical encounters in individuals vaccinated with ccIIV4 versus eIIV4 in the 2018–2019 US influenza season. These results support ccIIV4 as a potentially more effective public health measure against influenza than an egg-based equivalent. Oxford University Press 2021-01-05 /pmc/articles/PMC8326580/ /pubmed/33400775 http://dx.doi.org/10.1093/cid/ciaa1944 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Online Only Articles
Boikos, Constantina
Fischer, Lauren
O’Brien, Dan
Vasey, Joe
Sylvester, Gregg C
Mansi, James A
Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States
title Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States
title_full Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States
title_fullStr Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States
title_full_unstemmed Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States
title_short Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States
title_sort relative effectiveness of the cell-derived inactivated quadrivalent influenza vaccine versus egg-derived inactivated quadrivalent influenza vaccines in preventing influenza-related medical encounters during the 2018–2019 influenza season in the united states
topic Online Only Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326580/
https://www.ncbi.nlm.nih.gov/pubmed/33400775
http://dx.doi.org/10.1093/cid/ciaa1944
work_keys_str_mv AT boikosconstantina relativeeffectivenessofthecellderivedinactivatedquadrivalentinfluenzavaccineversuseggderivedinactivatedquadrivalentinfluenzavaccinesinpreventinginfluenzarelatedmedicalencountersduringthe20182019influenzaseasonintheunitedstates
AT fischerlauren relativeeffectivenessofthecellderivedinactivatedquadrivalentinfluenzavaccineversuseggderivedinactivatedquadrivalentinfluenzavaccinesinpreventinginfluenzarelatedmedicalencountersduringthe20182019influenzaseasonintheunitedstates
AT obriendan relativeeffectivenessofthecellderivedinactivatedquadrivalentinfluenzavaccineversuseggderivedinactivatedquadrivalentinfluenzavaccinesinpreventinginfluenzarelatedmedicalencountersduringthe20182019influenzaseasonintheunitedstates
AT vaseyjoe relativeeffectivenessofthecellderivedinactivatedquadrivalentinfluenzavaccineversuseggderivedinactivatedquadrivalentinfluenzavaccinesinpreventinginfluenzarelatedmedicalencountersduringthe20182019influenzaseasonintheunitedstates
AT sylvestergreggc relativeeffectivenessofthecellderivedinactivatedquadrivalentinfluenzavaccineversuseggderivedinactivatedquadrivalentinfluenzavaccinesinpreventinginfluenzarelatedmedicalencountersduringthe20182019influenzaseasonintheunitedstates
AT mansijamesa relativeeffectivenessofthecellderivedinactivatedquadrivalentinfluenzavaccineversuseggderivedinactivatedquadrivalentinfluenzavaccinesinpreventinginfluenzarelatedmedicalencountersduringthe20182019influenzaseasonintheunitedstates